Development of a Cell-Based Bioassay for Phospholipase A.sup.2-Triggered Liposomal Drug Release

The feasibility of exploiting secretory phospholipase A.sub.2 (sPLA.sub.2) enzymes, which are overexpressed in tumors, to activate drug release from liposomes precisely at the tumor site has been demonstrated before. Although the efficacy of the developed formulations was evaluated using in vitro an...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-05, Vol.10 (5)
Main Authors: Arouri, Ahmad, Trojnar, Jakub, Schmidt, Steffen, Hansen, Anders H, Mollenhauer, Jan, Mouritsen, Ole G
Format: Article
Language:English
Subjects:
Bioassay
Drug targeting
Health aspects
Liposomes
Methods
Phospholipases
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The feasibility of exploiting secretory phospholipase A.sub.2 (sPLA.sub.2) enzymes, which are overexpressed in tumors, to activate drug release from liposomes precisely at the tumor site has been demonstrated before. Although the efficacy of the developed formulations was evaluated using in vitro and in vivo models, the pattern of sPLA.sub.2 -assisted drug release is unknown due to the lack of a suitable bio-relevant model. We report here on the development of a novel bioluminescence living-cell-based luciferase assay for the monitoring of sPLA.sub.2 -triggered release of luciferin from liposomes. To this end, we engineered breast cancer cells to produce both luciferase and sPLA.sub.2 enzymes, where the latter is secreted to the extracellular medium. We report on setting up a robust and reproducible bioassay for testing sPLA.sub.2 -sensitive, luciferin remote-loaded liposomal formulations, using 1,2-distearoyl-sn-glycero-3-phosphatidylcholine/1,2-distearoyl-sn-glycero-3-phosphatidylglycerol (DSPC/DSPG) 7:3 and DSPC/DSPG/cholesterol 4:3:3 as initial test systems. Upon their addition to the cells, the liposomes were degraded almost instantaneously by sPLA.sub.2 releasing the encapsulated luciferin, which provided readout from the luciferase-expressing cells. Cholesterol enhanced the integrity of the formulation without affecting its susceptibility to sPLA.sub.2 . PEGylation of the liposomes only moderately broadened the release profile of luciferin. The provided bioassay represents a useful tool for monitoring active drug release in situ in real time as well as for testing and optimizing of sPLA.sub.2 -sensitive lipid formulations. In addition, the bioassay will pave the way for future in-depth in vitro and in vivo studies.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0125508